Liver transplant (LT) recipients are considered at a particularly high risk for developing critical COVID-19 infection. To date, available data are heterogeneous and scarce and mortality in LT recipients seems to be higher compared to normal population, but whether this is caused by altered immunological status, immunosuppression (IS), or underlying comorbidities has not yet been fully clarified. Some evidences show that IS might play a role in the pathophysiology of this new disease. We searched all available data regarding LT recipients infected by COVID-19, focusing on the role of IS. To date, 244 LT recipients have been reported as COVID-19-positive. Trends among transplant physicians are to reduce overall IS, especially antimetabolite drugs, but the current available observations are still not enough to build strong evidences for recommendation and IS should be meticulously tailored case by case.

COVID-19, liver transplant, and immunosuppression : Allies or foes? / A. Parente, T.M. Manzia, R. Angelico, F. Tirotta, P. Muiesan, G. Tisone, M. Framarino dei Malatesta. - In: TRANSPLANT INFECTIOUS DISEASE. - ISSN 1398-2273. - 23:1(2021), pp. e13417.1-e13417.6. [10.1111/tid.13417]

COVID-19, liver transplant, and immunosuppression : Allies or foes?

P. Muiesan;
2021

Abstract

Liver transplant (LT) recipients are considered at a particularly high risk for developing critical COVID-19 infection. To date, available data are heterogeneous and scarce and mortality in LT recipients seems to be higher compared to normal population, but whether this is caused by altered immunological status, immunosuppression (IS), or underlying comorbidities has not yet been fully clarified. Some evidences show that IS might play a role in the pathophysiology of this new disease. We searched all available data regarding LT recipients infected by COVID-19, focusing on the role of IS. To date, 244 LT recipients have been reported as COVID-19-positive. Trends among transplant physicians are to reduce overall IS, especially antimetabolite drugs, but the current available observations are still not enough to build strong evidences for recommendation and IS should be meticulously tailored case by case.
COVID-19; liver transplant; liver transplantation; Adolescent; Adult; COVID-19; Child; Female; Graft Rejection; Humans; Immunosuppressive Agents; Male; Middle Aged; Young Adult; Immunocompromised Host; Liver Transplantation; SARS-CoV-2; Transplant Recipients
Settore MED/18 - Chirurgia Generale
Article (author)
File in questo prodotto:
File Dimensione Formato  
2021-COVID-19, liver transplant, and immunosuppression.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 290.44 kB
Formato Adobe PDF
290.44 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/882329
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 7
social impact